Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Raised by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 5.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 50,660 shares of the company’s stock after purchasing an additional 2,677 shares during the period. Bank of New York Mellon Corp owned about 0.15% of Lexeo Therapeutics worth $333,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of LXEO. Rhumbline Advisers lifted its holdings in Lexeo Therapeutics by 19.6% during the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company’s stock worth $166,000 after buying an additional 4,127 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Lexeo Therapeutics in the fourth quarter worth $46,000. SG Americas Securities LLC bought a new stake in Lexeo Therapeutics during the fourth quarter valued at $72,000. JPMorgan Chase & Co. raised its holdings in shares of Lexeo Therapeutics by 135.6% during the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after purchasing an additional 5,915 shares during the period. Finally, Exome Asset Management LLC bought a new position in shares of Lexeo Therapeutics in the 3rd quarter worth about $797,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Trading Down 0.2 %

Shares of NASDAQ:LXEO opened at $4.10 on Friday. The company has a 50 day moving average of $4.05 and a 200-day moving average of $6.58. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market cap of $135.57 million, a P/E ratio of -1.30 and a beta of 3.85. Lexeo Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. As a group, analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LXEO has been the subject of a number of recent research reports. Leerink Partners lowered their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, March 24th. Royal Bank of Canada lowered their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $22.80.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.